Vanguard Group
BTTX

Vanguard Group’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Vanguard Group’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-198,154
Closed -$38.6K – 4505
2023
Q4 		$38.6K Sell
198,154
-301,743
-60% -$65.6K ﹤0.01% 4389
2023
Q3 		$183K Buy
499,897
+61,418
+14% +$41.4K ﹤0.01% 4266
2023
Q2 		$474K Hold
438,479
– – ﹤0.01% 4134
2023
Q1 		$307K Buy
438,479
+3,700
+0.9% +$4.35K ﹤0.01% 4242
2022
Q4 		$480K Buy
434,779
+135
+0% +$199 ﹤0.01% 4111
2022
Q3 		$765K Buy
434,644
+101,098
+30% +$184K ﹤0.01% 4082
2022
Q2 		$520K Buy
333,546
+49,151
+17% +$82.2K ﹤0.01% 4284
2022
Q1 		$563K Buy
284,395
+80,633
+40% +$279K ﹤0.01% 4375
2021
Q4 		$947K Buy
+203,762
New +$1.67M ﹤0.01% 4282

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Vanguard Group's BTTX Position: Q1 2024 in Review

Vanguard Group sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 198,154 shares — an estimated $38.6K sold.

Vanguard Group first reported a position in BTTX in Q4 2021 and held it in 9 quarters. The position peaked at $947K in Q4 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Vanguard Group reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 198,154 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $38.6K.
  • Vanguard Group first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Vanguard Group's Better Therapeutics, Inc. Common Stock position peaked at $947K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.